2025 POSTER PRESENTATIONS COMING IN MARCH

Here is a reminder of the 2024 Posters:

P001: Differentiation of Reversible from Irreversible Covalent Inhibitors by Enzyme Kinetic Assays, Presented by Matthew C., Amgen

P002: Complete Thermal Melting Characterization of the NISTmAb with the SUPR-DSF Microplate Reader, Presented by Marc N., Applied Photophysics, Inc.

P003: Column Head Loading in SFC - A Unique Sample Injection Technique for Polar Heterocycles and Oligopeptides, Presented by Somesh S., Aragen Life Sciences

P004: Production of Diverse Sets of Therapeutically Relevant, Novel Amino Acids via Biocatalysis, Presented by Wendy H., Aralez Bio

P005: A Proven Activity-Based Workflow for the Identification and Characterization of Time-Dependent Kinase Inhibitors using a Continuous Assay Format, Presented by Jane L., AssayQuant Technologies, Inc.

P006: Development of a Highly Potent Covalent BTK PROTAC: Sub-Stoichiometric Degradation is Dispensable, Presented by Ran C., Baylor College of Medicine

P007: COOKIE-Pro: A Chemoproteomics Method for Covalent Inhibitor Binding Kinetics Profiling, Presented by Hanfeng L., Baylor College of Medicine

P008: A Simple and Robust Cell-Based Assay for Evaluating GLP-1R, GIPR, and GCGR Agonists, Presented by Ava B., BPS Bioscience, Inc.

P009: Gaining Insights from the Cambridge Structural Database (CSD), Presented by Charlotte Y., Cambridge Crystallographic Data Center

P010: Deep Characterization of Binding Kinetics for 210 Kinase Inhibitors Against 80+ Kinases, Presented by Rebecca R., Carterra, Inc.

P011: Apolipoprotein E: Purification, Characterization, and Lipid Nanoparticle Uptake Enhancement, Presented by Zahra A., Cayman Chemical Company

P012: Calcium-Dependent Hit Identification for PAD4 Inhibitors with FDA-Approved and Fragment-Based Library Approaches, Presented by Marie F., Cayman Chemical Company

P013: Fragment-Based Drug Discovery (FBDD) Approach for Acetylcholinesterase, Presented by Kendall M., Cayman Chemical Company

P014: MICRO-TAG: A Novel Fluorescence-Based Real-Time Cellular Target Engagement Platform for Drug Discovery, Presented by Ivan B., CellarisBio

P015: Pan-RAS Inhibitor ADT-007: A Novel Mechanism of Antitumor Selectivity in PDAC and CRC Carcinoma Models, Presented by Ivan B., CellarisBio

P016: Chd4, Foxp3+ Treg Cells and Tumor Immunotherapy, Presented by Elmar N., CellarisBio

P017: Probing Monomer – Dimer and Conformational Transitions of PLK1 Using Catalytic and Polo-Box Domain Inhibitors, Presented by Elmar N., CellarisBio

P018: R9: A Novel NuRD Complex Inhibitor for Targeted Therapy in Triple Negative Breast Cancer (TNBC), Presented by Elmar N., CellarisBio

P019: CF-PPiD: A Cell-Free Human Protein Array Technology Using Proximity Biotinylation-Based Protein-Protein Interaction Identification, Presented by Intisar M., CellFree Sciences Co., Ltd.

P020: Integrated Drug Discovery – PD-1/PD-L1 Inhibitors, Presented by James H., Charnwood Discovery

P021: Discovery of Brain-Penetrant NLRP3 Inhibitors to Treat Inflammatory Diseases, Presented by Michael N., ChemDiv, Inc.

P022: Discovery of NSP14 Inhibitors of SARS-CoV-2, Presented by Roman T., ChemDiv, Inc.

P023: Integrate Machine Learning and Automation to Advance Retrosynthesis Planning and Custom Chemical Synthesis, Presented by Arthur L., Chemical.ai

P024: A Knowledge-Based Fragment Library Design Platform and an In-Silico Platform for Rapid Fragment Optimization, Presented by Gergely M., ChemPass Ltd.

P025: Unveiling Hidden Treasures: Exploring Large Chemical Spaces with Machine Learning Models Trained on DNA-Encoded Libraries, Presented by Olena S., Chemspace LLC

P026: REAL Fragment Library: Efficient Fragment Growing Inside Enamine REAL Using Exit Vector Analysis, Presented by Olga T., Chemspace LLC

P027: Introducing BioPALS – A Versatile Hit Identification Technology Powered by AI and Enabled by GCI, Presented by Tom P., Concept Life Sciences

P028: PROTAC Design Using Electrostatic Complementarity™, Presented by Sylvie S., Cresset

P029: Experimental Strategies for Fragment-Based Screening of Challenging Targets Using Surface Plasmon Resonance, Presented by Cynthia S., Cytiva

P030: Accelerating Drug Discovery with an Iterative and Evolutionary Generative Approach, Presented by Kevin C., Dassault Systemes BIOVIA

P031: Accelerated Direct-to-Biology Facilitated by Plate-Based Reaction Optimisation and a Partial PROTAC Library, Presented by Ray B., Domainex Ltd.

P032: AS-MS for the Discovery of Novel Ligands for Membrane Proteins, Presented by Jean-Yves O., Edelris SAS

P033: Development of Thalidomide Derivatives for Controlling Neosubstrate Degradation, Presented by Satoshi Y., Ehime University

P034: Bridging the Data Gap: Leveraging Internal Data for Caco-2 Permeability Prediction using Deep Learning, Presented by Adi H., Eikon Therapeutics

P035: Analysis of HDAC6:Tubulin Interaction Using Affinity Selection Mass Spectrometry, Presented by Ryan K., Eli Lilly and Company

P036: Biophysics in Kinase Drug Discovery Programs: From Fragment-Based Screening Campaigns to PROTAC Ternary Complex Characterization, Presented by Vanessa P., Eurofins Discovery

P037: Mapping Trace Amine-Associated Receptor 1 with Positron Emission Tomography, Presented by Achi H., F. Hoffmann-La Roche Ltd.

P038: Applying Flow Induced Dispersion Analysis for In-Solution Binding Kinetics, Presented by Hasse H., Fida Biosystems

P039: Structural Analysis of the Complex Model of Ambrosia artemisiifolia PPO2 and OMN for Understanding Herbicide Resistance Mechanisms, Presented by Eunju K., Gyeongsang National University

P040: Advancements in EPR Technology for Automated Determination of Protein Structural Constraints, Presented by Austin GJ., High Q Technologies

P041: Hyper Lab: Drug Discovery Platform Using a Deep Learning-Based Protein-Ligand Interaction Prediction Model, Presented by Hyun Joon C., HITS Co., Ltd.

P042: Advancing Biocuration and Ligand Design with Large Language Models for Rare Diseases, Presented by Parthiban S., Indian Institute of Science Education and Research

P043: Exploring Biomedical Data with Knowledge Graphs and Generative AI models for Muscular Dystrophy, Presented by Parthiban S., Indian Institute of Science Education and Research

P044: A Lean Optimized Fragment Library for Crystallographic Fragment Screening, Presented by ThirumalaiSelvi U., IniXium

P045: Rational Fragment-Based Approach to Targeting the LEDGF PWWP Domain in HIV Infection and MLL-r Leukemia, Presented by Thibault V., Katholieke Universiteit Leuven

P046: De Novo Screening and Mirror-Image Isomerization of Peptides Targeting nAChR, Presented by Yuyuan W., Ks-v Peptide

P047: Empowering Peptide Discovery via KPDS™ Platform, Presented by Yuyuan W., Ks-v Peptide

P048: Fragment Compound Libraries from Life Chemicals, Presented by George B., Life Chemicals, Inc.

P049: Screening Compound Libraries for HTS and Lead Discovery Projects, Presented by George B., Life Chemicals, Inc.

P050: Covalent Inhibitor Screening Libraries, Presented by Vasily P., Life Chemicals, Inc.

P051: Novel RNA-Focused Screening Libraries for Modern Drug Discovery, Presented by Vasily P., Life Chemicals, Inc.

P052: From Virtual to Reality: Representing Ultra-Large Virtual Libraries Through a Diverse (Physical) Sub-Set for HTS, Presented by Ilaria PS., Liverpool ChiroChem Ltd.

P053: Kinetic Screening Using Grating Coupled Interferometry (GCI) – Highly Sensitive Biosensor-Based Assays Enable the Identification of Weak Fragment Hits Across a Diverse Set of Challenging Targets, Presented by Kiel J., Malvern Panalytical

P054: Unlocking Cancer's Achilles Heel: Targeting Anti-Oxidative Capacity for Potential Cure, Presented by Sinto C., Mayo Clinic

P055: Modulation of Calcium-Release Activated Channels by Peptide-Based Macrocycles, Presented by Pedro SM., Medical University of Graz

P056: Aspartyl(asparaginyl)-beta-hydroxylase (ASPH) Inhibitors for Treatment of Cancer, Presented by Mark O., Midwestern University

P057: Computational Design of Brain Penetrating ALKBH5 Inhibitors, Presented by Margaret O., Anthem Preparatory Academy

P058: Fast Molecular Conformer Generation by Chemical Graph Convolution Neural Network in Internal Coordinates, Presented by Maxim T., Molsoft

P059: To Affinity and Beyond: Biophysical Methods Enable Fragment-to-Lead Development for Fatty Acid Binding Protein 4, Presented by Indu C., Monash University

P060: Fragment-Based Development of nM FABP4 Binders Through Rapid SPR Screening of Crude Reaction Libraries, Presented by Jason P., Monash University

P061: Integrating Cryo-EM into Structural Toxicology: Addressing Off-Target Effects and Optimizing Drug Development, Presented by Claudio C., NanoImaging Services

P062: Discovering Furanopyrimidine-Based Dual MER and AXL Inhibitors as Immunomodulatory Anticancer Treatments, Presented by Hsing-Pang H., National Health Research Institutes, Taiwan

P063: Opportunities for the Development of Neurotherapeutics: NIH Blueprint Neurotherapeutics Network (BPN), Presented by Enrique M., National Institutes of Health, National Institute of Mental Health

P064: Opportunities for the Development of Neurotherapeutics: NINDS Division of Translational Research, Presented by Charles C., National Institutes of Health, National Institute of Neurological Disorders and Stroke

P065: Covalent Fragment Optimization Applied to Epidermal Growth Factor Receptor Tyrosine Kinase, Presented by Hannah S., Newcastle University

P066: Fragment Expansion with NUDELs - Poised DNA-Encoded Libraries, Presented by Mike W., Newcastle University

P067: Exploring Antibody Surface Representations, Presented by Addison S., OpenEye Cadence Molecular Sciences

P068: The FFCS Pipeline: Streamlining Crystallographic Screening for FBDD at the SLS, Presented by Alexander M., Paul Scherrer Institut

P069: Targeted Protein Degradation Drug Discovery Using the Cellular Thermal Shift Assay (CETSA®), Presented by Michael D., Pelago Bioscience AB

P070: Exploring Targeted Protein Degraders: Research, Development and Manufacturing, Presented by Zhenzhen D., PharmaBlock

P071: A Drug Discovery Platform Enabling Robust Intracellular Delivery of Cell Impermeable Cargo via Mechanoporation, Presented by Sophia H., Portal Biotechnologies

P072: Streamlining Cellular Signaling Analysis: Lumit® Immunoassays for Rapid Monitoring of Protein Phosphorylation and Degradation, Presented by Michael C., Promega Corporation

P073: Chemical Proteomic Strategy Utilizing a Photoreactive Chloroalkane Capture Tag for Target Discovery, Presented by Steven E., Promega Corporation

P074: Developing Novel NanoBRET™ Target Engagement Assays Using NanoBRET™ 590 Dyes, Presented by Alissa K., Promega Corporation

P075: First-in-Class Selectivity System for Quantitative Kinase Inhibitor Profiling in Live Cells Against 192 Kinases, Presented by Amy L., Promega Corporation

P076: A NanoBRET™ Target Engagement Assay for Querying Domain Selectivity at Full-Length Polymerase Theta in Live Cells, Presented by James V., Promega Corporation

P077: Exploring the Landscape of PARP and PARG Inhibitor Selectivity in Live Cells Using NanoBRET™ Target Engagement Assays, Presented by Min Z, Promega Corporation

P078: Phenotypic Screening and Inferential Search with High-Throughput All-Optical Electrophysiology to Identify Novel Compounds and Target Mechanisms for Tuberous Sclerosis, Presented by Steven R., Quiver Bioscience

P079: Rapaglues: Macrocyclic Libraries Inspired from Rapamycin, Presented by Sam H., Rapafusyn Pharmaceuticals

P080: Two Approaches Aiming to Prevent Phosphorylation of SMARCA4 by CDK9 Using WAC and In Silico Screening, Presented by Johan E., Red Glead Discovery AB

P081: Successful Application of an RNA Splicing Modulator Platform to Develop Molecules Targeting the Transcription Factor MYB to Treat Solid and Blood Cancers, Presented by Thomas W., Rgenta Therapeutics

P082: Structure-Based Drug Discovery for MtCK and GCDH Using Cryo-EM, Presented by Merve D., Sanford Burnham Prebys Medical Discovery Institute

P083: Discovery and Development of Novel Autophagy Inhibiting ATG13 Degrading Compounds, Presented by Patrick H., Sanford Burnham Prebys Medical Discovery Institute

P084: Discovery and Characterization of Novel Fragment Binders of the VHR Phosphatase as a Drug Target for Cervix Cancer, Presented by Emily W., Sanford Burnham Prebys Medical Discovery Institute

P085: Fragment Screening of IL-23 by Weak Affinity Chromatography (WAC), Presented by Kenth H., SARomics Biostructures AB

P086: Natural Product Inhibitors of the Cyclic GMP-AMP Synthase (cGAS) – Stimulator of Interferon Genes (STING) Pathway, Presented by Mildred K., Scripps Research Institute

P087: Development of Novel X-Ray Crystallography Services at Selvita, Presented by Aleksandra B., Selvita

P088: Best of Both Worlds: An Expansion of the State of the Art pKa Model with Data from Three Industrial Partners, Presented by Eric J., Simulations Plus, Inc.

P089: Building Diverse Hit-Finding Collections Through Novel Chemistries - Sygnature Discovery’s Unique PRISM Library for HTS, Presented by Allan J., Sygnature Discovery

P090: The Sygnature CHARMED Platform: Combinatorial High-Throughput Assembly and Review of Molecular Degraders, Presented by Allan J., Sygnature Discovery

P091: Tandem QuickCycle: High-Speed Optimization of Compounds Using Generative Design and Machine Learning, Presented by Chuan T., TandemAI

P092: Revolutionizing Small Molecule Drug Discovery Pipelines with Cryo-EM: A Workflow for High-Throughput Screening and High-Resolution Data Collection, Presented by Dominic M., Thermo Fisher Scientific

P093: Predicting Structural Ensemble of Cyclic Peptides in Solution: Exploring the Potential of Molecular Dynamics Simulations and Force Fields for Cyclic Peptide Drug Design, Presented by Arghya G., Tufts University

P094: Macrocyclic Peptide Permeability Studying via A Fluorogenic CuAAC-Based Liposomal Permeation Assay, Presented by Juan H., University of California, Irvine

P095: Unraveling Cysteine Reactivity for Therapeutic Targeting by Integrating Chemoproteomics and Computational Sciences, Presented by Lisa B., University of California, Los Angeles

P096: Targeted Degradation of Pin1 by Protein Destabilizing Compounds, Presented by Giulia A., University of California, Riverside

P097: Targeting hMcl-1 with Histidine-Covalent Agents, Presented by Giulia A., University of California, Riverside

P098: Targefrin: A Targeted Anti-Metastatic Therapeutic for Pancreatic Cancer, Presented by Carlo B., University of California, Riverside

P099: Novel Screening Strategies and Approaches Targeting KRAS, Presented by Sara C., University of California, Riverside

P100: Stabilized β-Hairpins Targeting the Ligand Binding Domain of EphA4, Presented by Anne Marie P., University of California, Riverside

P101: Investigation of the Pharmacological Inhibition of Novel Covalent Pin1 Degraders, Presented by Parima U., University of California, Riverside

P102: Develop New Chemical Tool and Chemo-Proteomic Experiments for Studying Superoxide (O2•-) Biology, Presented by Hin Yuk L., University of Hong Kong

P103: Development of PMO-Based RNA Degraders for the Treatment of Parkinson's Disease, Presented by Shalakha H., University of Kansas

P104: cgSHAPE-seq Informs the Binding Site of RNA-Degrading Chimeras Targeting SARS-CoV-2 5’ UTR, Presented by Zhichao T., University of Kansas

P105: Fragment-Based Discovery of Potent PRC1 Inhibitor with In Vivo Efficacy in Leukemia, Presented by Yiwu Y., University of Michigan

P106: Development of Novel Cell-Permeable Macrocyclic Peptide Inhibitors for Oncological Target MAGE-A4, Presented by Jiwoong L., University of North Carolina at Chapel Hill

P107: Discovery of a Novel Chikungunya Virus nsP2 Protease Inhibitor Using a Covalent Fragment-Based Screening Approach, Presented by Eric M., University of North Carolina at Chapel Hill

P108: Fragments to Leads: Accelerating Discovery by Rapid Screening of Giga-Scale On-Demand Chemical Spaces, Presented by Antonina N., University of Southern California

P109: Utilizing Rapid Active Learning Docking as an Efficient Tool to Explore Multiple Novel Binding Sites in Parallel, Presented by Laust M., University of Southern Denmark

P110: Augmented Radionuclide Stimulated Therapy Evaluation for Improved Cancer Treatment Response, Presented by Christopher E., University of Texas, Dallas

P111: DELs in Cells: Turn-Around-Time Optimized, Presented by Leif L., Vipergen Aps

P112: Unleash the Greatest Potential of DEL: Viva’s High-Value, High-Capability DNA-Encoded Library Platform, Presented by Bing X., Viva Biotech Ltd.

P113: A Novel Screening Platform for Discovery of Selective RNA-Targeting Small Molecules that Modulate Disease-Associated RNA Structures, Presented by Michelle K., Wayfinder Biosciences

P114: CardioGenAI: A Machine Learning-Based Framework for Re-Engineering Drugs for Reduced hERG Liability, Presented by Gregory K., Yale University

P115: Cloud Enabled NGS-Based Antibody Discovery and 3D Antibody Structural Modeling, Presented by Eric A., OpenEye Cadence Molecular Sciences

P116: The Development of Novel 4-Aminoquinolines as Therapeutics Against Multidrug Resistant Malaria, Presented by Mason H., Oregon Health and Science University